{
    "Trade/Device Name(s)": [
        "Immunalysis Tapentadol Urine HEIA\u2122"
    ],
    "Submitter Information": "Immunalysis Corporation",
    "510(k) Number": "K203527",
    "Predicate Device Reference 510(k) Number(s)": [
        "K141803"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DJG"
    ],
    "Summary Letter Date": "February 10, 2022",
    "Summary Letter Received Date": "February 11, 2022",
    "Submission Date": "February 10, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.3650"
    ],
    "Regulation Name(s)": [
        "Opiate Test System"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Tapentadol"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Automated clinical chemistry analyzer",
        "Beckman Coulter AU480 chemistry analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Homogeneous enzyme immunoassay"
    ],
    "Methodologies": [
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for Immunalysis Tapentadol Urine HEIA\u2122 homogeneous enzyme immunoassay for qualitative and semi-quantitative detection of tapentadol in human urine using automated clinical chemistry analyzers",
    "Indications for Use Summary": "For in vitro diagnostic use in laboratories for qualitative and semi-quantitative analysis of tapentadol in human urine with automated clinical chemistry analyzers; provides preliminary analytical test result, requiring confirmatory testing by GC-MS or LC-MS/MS",
    "fda_folder": "Toxicology"
}